The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results.
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Black Diamond Therapeutics; Blue Earth Diagnostics; Boston Pharmaceuticals; Celularity; Chimerix; Day One Biopharmaceuticals; ElevateBio; Imvax; Integral Health; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Novocure; Nuvation Bio; Prelude Therapeutics; QED Therapeutics; Sapience Therapeutics; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Research Funding - Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Chimerix (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
John Frederick de Groot
Employment - ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; WuXi Biologics; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; Agios; Bioasis Technologies; Cure Brain Cancer Foundation; Debiopharm Group; DelMar Pharmaceuticals; Genentech/Roche; GenomiCare; GlaxoSmithKline; InSightec; Janssen; Karyopharm Therapeutics; KIYATEC; Magnolia Innovation; Merck; Monteris Medical; Mundipharma Research; Novartis; Prelude Therapeutics; resTORbio; Samus Therapeutics; Sapience Therapeutics; Tocagen; Voyager Therapeutics
Research Funding - CarThera (Inst); Haihe Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - VBI Vaccines
 
James Battiste
Other Relationship - SVN Med
 
Samuel A. Goldlust
Employment - Regional Cancer Care Associates
Leadership - Cellevolve
Stock and Other Ownership Interests - COTA
Honoraria - Cornerstone Specialty Network; Daiichi Sankyo/Astra Zeneca; Physicans' Education Resource
Consulting or Advisory Role - Boston Biomedical; Cellevolve; Novocure; Sumitomo Dainippon Pharma Oncology
Speakers' Bureau - Novocure
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Cantex Pharmaceuticals (Inst); Celgene (Inst); Celldex (Inst); Celularity (Inst); CNS Healthcare (Inst); Cortice Biosciences (Inst); Diffusion Pharmaceuticals (Inst); ImmunoCellular Therapeutics (Inst); Imvax (Inst); Imvax (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Merck (Inst); Northwest Biotherapeutics (Inst); Novocure (Inst); Novogen (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tocagen (Inst); Wex Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Kyowa Kirin International; Novocure
 
James Stuart Garner
Employment - Kazia Therapeutics
Leadership - Kazia Therapeutics
Stock and Other Ownership Interests - Kazia Therapeutics
 
John Friend
Employment - Helsinn Therapeutics; Kazia Therapeutics
Leadership - Helsinn Therapeutics; Kazia Therapeutics
Stock and Other Ownership Interests - Kazia Therapeutics
 
Jeremy Andrew Simpson
Employment - Kazia Therapeutics
Leadership - Kazia Therapeutics
Stock and Other Ownership Interests - Kazia Therapeutics
 
Denise Damek
Research Funding - Kazia Therapeutics (Inst); NovoCure (Inst)
 
Alan Olivero
Stock and Other Ownership Interests - Kazia Therapeutics; Roche
Consulting or Advisory Role - Genentech/Roche; Imugene; Kazia Therapeutics; ORIC Pharmaceuticals
Patents, Royalties, Other Intellectual Property - I have patents from my employment with Genentech/Roche
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Chimerix; Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; DelMar Pharmaceuticals; DNAtrix; Global Coalition for Adaptive Research; GW Pharmaceuticals; Inovio Pharmaceuticals; Karyopharm Therapeutics; Katmai Pharmaceuticals; KIYATEC; Merck; Novartis; Pascal Biosciences; Pfizer; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; Tocagen; VBI Vaccines; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Break Through Cancer; Global Coalition for Adaptive Research